Hemispherx Biopharma retires all outstanding convertible debentures

By Sheri Kasprzak

New York, July 2 - Hemispherx Biopharma, Inc. has retired all of its outstanding convertible debentures.

Of the $4.1 million in principal of the debentures, only $1,643,960 was required to be paid in new funds to retire the debentures. The rest was covered by other cash and securities already held in collateral for the debentures.

The debentures were issued in October 2003, January 2004 and July 2004.

Philadelphia-based Hemispherx develops drugs to treat debilitating disorders, like viral diseases and immune-system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.